Many Eligible Patients Still Lack Access to GLP-1 Weight-Loss Drugs

Boston University School of Public Health

A new study found that prescriptions for the revolutionary drugs for weight management were lower among younger and older adults, men, Black and Hispanic patients, patients in lower BMI categories, and those whose healthcare providers were located in lower socioeconomic neighborhoods.

In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health, and other emerging uses. But not all populations are benefitting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).

Published in the journal Health Affairs Scholar , the study found that the percentage of patients with overweight or obesity and without type 2 diabetes who filled prescriptions for semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) within six months of becoming eligible surged from 1.9 percent in 2021 to 16.6 percent in 2025. But prescriptions for these medications were lower among patients who were men, Black or Hispanic, younger or older (ages 18-34 or 55-64), in a lower BMI category, and/or whose healthcare provider was located in a neighborhood with lower socioeconomic status (SES), measured by education levels in the provider's ZIP code.

These disparities widened over time, and were particularly pronounced in 2024 and 2025, after semaglutide and tirzepatide received formal approval by the Food and Drug Administration for chronic weight management in 2021 and 2023, respectively. The study was funded by the Robert Wood Johnson Foundation (RWJF) and the American Heart Association.

By mimicking a natural hormone that helps regulate insulin, blood sugar, appetite, and digestion, GLP-1s can help people achieve dramatic weight loss, particularly those who struggle to lose weight through traditional diet and exercise. Health experts worry that persistent challenges with GLP-1 accessibility and affordability are hindering large swaths of eligible people from receiving life-changing, and potentially life-saving, treatment.

"Our study focuses on a population that is especially vulnerable to inequities in GLP-1 access," says study senior author Dr. Andrew Stokes , associate professor of global health at BUSPH, who studies population health, aging, and mortality, including inequities in GLP-1 access . "We have better treatments for obesity than ever, but access to them hasn't caught up. It is much easier for people with diabetes to get these drugs covered by insurance. But for people living with overweight or obesity, coverage is very difficult to obtain—even when they qualify—because providers and insurers don't always view these as conditions that merit treatment. This is a population that has been left behind."

As these medications continue to gain prominence, the findings underscore the need for healthcare providers to receive appropriate training and resources about prescribing GLP-1 treatments, as well as the need for improvements in insurance companies' drug benefit design to ensure that people who qualify for these treatments can easily access them.

"GLP-1 receptor agonists are moving into routine care very quickly, but without deliberate action, these drugs risk widening the health inequities that obesity already reflects," says study lead and corresponding author Dr. Minh Trung Le , research data analyst in the Department of Global Health at BUSPH at the time of the study.

Dr. Stokes and Dr. Le utilized medical claims data from a national database that includes closed claims for more than 175 million patients. For the analysis, they examined health information, GLP-1 treatment, and healthcare provider locations among 512,389 eligible, commercially insured patients ages 18-64. The analysis did not include patients covered by Medicaid or Medicare, people without insurance, or prescriptions obtained through direct-to-consumer channels.

Despite the nearly ninefold rise in GLP-1 prescriptions among eligible patients during the study period, the researchers point out that the vast majority of eligible patients still do not receive these prescriptions for weight management. People with employer-sponsored and other commercial insurance are more likely to have access to GLP-1s. That racial disparities in access to these medications were still evident among the study's commercially insured participants underscores the long-standing structural barriers to healthcare that Black and Hispanic patients experience, even as they are burdened by obesity and other health conditions at greater rates than other populations. Black and Hispanic patients are more likely to face biases and stigma in healthcare, mistrust of the healthcare system, and higher medication costs, all of which can exacerbate racial disparities in GLP-1 uptake.

The expansion in GLP-1 medication use also disproportionately benefited patients who saw providers in higher-SES neighborhoods. These SES disparities were smaller in the beginning of the study period, but widened over time, and were larger among patients in lower BMI categories. These disparities were also particularly pronounced among men, which the researchers say may reflect men's lower likelihood of seeking weight-management care.

"Patients seen at clinics in lower-socioeconomic neighborhoods had about 35 percent lower odds of being prescribed semaglutide or tirzepatide in 2024–2025; early on, that gap was about 15 percent," says Dr. Le. Insurance coverage alone doesn't close the gap, he says. "We need to look at how drug benefits are designed, including prior authorization, step therapy , and out-of-pocket costs that land unevenly on different patients. We also need to give under-resourced practices real support, such as help with prior-authorization paperwork, so that a clinic's administrative capacity doesn't decide who gets treated."

"These important results show how emerging patterns of GLP-1 access reflect the inequity and fragmentation of our overall healthcare system, where access to affordable care is all too often a function of where you work, what state you live in, or how much money you have," says Dr. Katherine Hempstead , who was not involved in the study, and is a senior policy officer at the Robert Wood Johnson Foundation studying health issues and policies related to health insurance, costs, and access to care. Wealthier patients—many of whom may not clinically qualify for weight-management medications—are often able to leverage their network and resources to pay out-of-pocket for these medications, she adds. "The new direct-to-consumer channels for GLP-1s are increasing inequity, as ability to pay, rather than need or potential benefit, is what determines access. Because of the poor incentives and shortsightedness in our system, we are leaving major population health benefits on the table, since many of those who would benefit the most from these medications can't afford them."

The researchers say the findings add urgency to a growing shift in the healthcare field to view obesity as a chronic disease, rather than a personal responsibility or lifestyle failure.

"A doctor would never tell a patient with diabetes or with heart disease that their only option is to 'modify their dietary regimes' or 'exercise more,'" Dr. Stokes says. "When you think about obesity as a disease, it implies the value of effective medical treatment for the clinical factors that need to be addressed."

**

About Boston University School of Public Health

Founded in 1976, Boston University School of Public Health is one of the top ten ranked schools of public health in the world. It offers master's- and doctoral-level education in public health. The faculty in six departments conduct policy-changing public health research around the world, with the mission of improving the health of populations—especially the disadvantaged, underserved, and vulnerable—locally and globally.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.